Chubb’s $1 million contribution to The Rockefeller University, the world’s leading biomedical research university, will support work now underway by over 130 scientists in more than 20 laboratories focused on discovering or developing new, urgently needed approaches to prevent and treat the COVID-19 disease. The University’s research teams are actively working to identify new preventions and therapies to slow the momentum of the COVID-19 pandemic with cutting-edge biomedical research.
Rockefeller scientists are attacking COVID-19 from multiple angles focused on developing novel preventions and treatments, a therapeutic vaccine, and better tests.
Scientists are using ‘elite’ antibodies from COVID-19 survivors to develop potent therapies.
Learn more about The Rockefeller University on their website.